BR112014017834A8 - Sistema de distribuição de fármacos - Google Patents

Sistema de distribuição de fármacos

Info

Publication number
BR112014017834A8
BR112014017834A8 BR112014017834A BR112014017834A BR112014017834A8 BR 112014017834 A8 BR112014017834 A8 BR 112014017834A8 BR 112014017834 A BR112014017834 A BR 112014017834A BR 112014017834 A BR112014017834 A BR 112014017834A BR 112014017834 A8 BR112014017834 A8 BR 112014017834A8
Authority
BR
Brazil
Prior art keywords
core
delivery system
membrane
distribution system
active substance
Prior art date
Application number
BR112014017834A
Other languages
English (en)
Other versions
BR112014017834B1 (pt
BR112014017834A2 (pt
Inventor
Lyytikäinen Heikki
Jukarainen Harri
Original Assignee
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014017834(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Oy filed Critical Bayer Oy
Publication of BR112014017834A2 publication Critical patent/BR112014017834A2/pt
Publication of BR112014017834A8 publication Critical patent/BR112014017834A8/pt
Publication of BR112014017834B1 publication Critical patent/BR112014017834B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • External Artificial Organs (AREA)

Abstract

SISTEMA DE DISTRIBUIÇÃO DE DROGAS. A presente invenção refere-se a um novo sistema de distribuição de droga para a liberação controlada de substância(s) terapeuticamente ativa(s) em uma taxa de liberação predeterminada, essencialmente constante através de um período de tempo prolongado. O sistema de distribuição compreende pelo menos um núcleo compreendendo a(s) dita(s)substância(s) terapeuticamente ativa(s), pelo menos uma membrana encerrando o núcleo e uma camada inter mediária de um material substancialmente inerte, em que a camada intermediária é aplicada entre o núcleo e a membrana ou entre duas camadas de membrana.
BR112014017834-8A 2012-01-23 2013-01-22 sistema de distribuição de fármacos BR112014017834B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20125069 2012-01-23
FI20125069 2012-01-23
PCT/FI2013/050068 WO2013110856A1 (en) 2012-01-23 2013-01-22 A drug delivery system

Publications (3)

Publication Number Publication Date
BR112014017834A2 BR112014017834A2 (pt) 2017-06-20
BR112014017834A8 true BR112014017834A8 (pt) 2017-07-11
BR112014017834B1 BR112014017834B1 (pt) 2021-05-18

Family

ID=47666152

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017834-8A BR112014017834B1 (pt) 2012-01-23 2013-01-22 sistema de distribuição de fármacos

Country Status (39)

Country Link
US (1) US10500381B2 (pt)
EP (1) EP2806893B1 (pt)
JP (1) JP6236401B2 (pt)
KR (1) KR102004014B1 (pt)
CN (1) CN104144702B (pt)
AR (1) AR089765A1 (pt)
AU (1) AU2013213514B2 (pt)
BR (1) BR112014017834B1 (pt)
CA (1) CA2861947A1 (pt)
CL (1) CL2014001935A1 (pt)
CO (1) CO7020911A2 (pt)
CR (1) CR20140358A (pt)
CU (1) CU24431B1 (pt)
CY (1) CY1120773T1 (pt)
DK (1) DK2806893T3 (pt)
DO (1) DOP2014000171A (pt)
EA (1) EA032208B1 (pt)
EC (1) ECSP14010605A (pt)
ES (1) ES2691635T3 (pt)
HK (1) HK1203802A1 (pt)
HR (1) HRP20181707T1 (pt)
IL (1) IL233599B (pt)
LT (1) LT2806893T (pt)
MX (1) MX355961B (pt)
MY (1) MY172812A (pt)
NZ (1) NZ627461A (pt)
PE (1) PE20141818A1 (pt)
PH (1) PH12014501654B1 (pt)
PL (1) PL2806893T3 (pt)
PT (1) PT2806893T (pt)
RS (1) RS57911B1 (pt)
SG (1) SG11201404032SA (pt)
SI (1) SI2806893T1 (pt)
TR (1) TR201815247T4 (pt)
TW (1) TWI626951B (pt)
UA (1) UA116197C2 (pt)
UY (1) UY34583A (pt)
WO (1) WO2013110856A1 (pt)
ZA (1) ZA201406206B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105050708A (zh) 2012-11-14 2015-11-11 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
KR20170021929A (ko) * 2014-06-28 2017-03-02 라보라토리오스 안드로마코 에스.에이. 조산 예방에 유용한 지속적, 서방성, 및 연속 방출의 프로게스테론 함유 원형 결찰 페서리
KR20180093255A (ko) * 2015-12-21 2018-08-21 바이엘 오와이 질용 고리의 제조 방법
WO2018202574A1 (en) 2017-05-04 2018-11-08 Bayer Oy Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception
JP7242648B2 (ja) * 2017-09-27 2023-03-20 バイエル・オサケユキテュア エラストマーマトリックスからの治療活性剤の放出を変更するための方法
CN109954198B (zh) * 2017-12-25 2021-10-12 先健科技(深圳)有限公司 药物球囊及其制备方法
CN113677326A (zh) * 2019-02-19 2021-11-19 粒子科学公司 隔室化药物递送装置

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
AU2001258442A1 (en) 2000-05-10 2001-11-20 Leiras Oy Drug delivery device, especially for the delivery of levonorgestrel
AU2002210580A1 (en) * 2000-10-20 2002-04-29 Leiras Oy Drug delivery system
AU2002313517B2 (en) * 2001-08-31 2007-09-06 Bayer Schering Pharma Oy Drug delivery system
DE10209979A1 (de) 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
PL2319500T3 (pl) 2004-03-12 2013-05-31 Biodel Inc Szybko działające kompozycje do dostarczania leku
DE602004008912T3 (de) 2004-07-13 2012-09-13 Bayer Schering Pharma Oy Retardiertes Freigabesystem mit kontrollierter Initialabgabe
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20090208575A1 (en) * 2005-01-03 2009-08-20 Lupin Limited Pharmaceutical Composition Of Acid Labile Substances
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US8137327B2 (en) 2006-06-16 2012-03-20 Family Health International Vaginal drug delivery system and method
WO2008061963A2 (en) * 2006-11-20 2008-05-29 N.V. Organon Helically-shaped drug delivery system
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
EP2140860A1 (en) 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
FI121000B (fi) 2008-11-19 2010-06-15 Bayer Schering Pharma Oy Intravaginaalinen antojärjestelmä ja menetelmä sen valmistamiseksi
WO2012092283A1 (en) * 2010-12-27 2012-07-05 Dow Corning Corporation Drug delivery dispersion and film formed therefrom

Also Published As

Publication number Publication date
MX2014008906A (es) 2014-08-26
US10500381B2 (en) 2019-12-10
MX355961B (es) 2018-05-07
PE20141818A1 (es) 2014-12-18
TW201343204A (zh) 2013-11-01
CR20140358A (es) 2014-11-17
ZA201406206B (en) 2019-06-26
TWI626951B (zh) 2018-06-21
KR102004014B1 (ko) 2019-07-25
CO7020911A2 (es) 2014-08-11
NZ627461A (en) 2016-07-29
CY1120773T1 (el) 2019-12-11
EA201400834A1 (ru) 2014-12-30
EP2806893A1 (en) 2014-12-03
CN104144702B (zh) 2018-03-06
US20140350488A1 (en) 2014-11-27
TR201815247T4 (tr) 2018-11-21
BR112014017834B1 (pt) 2021-05-18
IL233599B (en) 2019-07-31
ECSP14010605A (es) 2015-12-31
CU20140094A7 (es) 2014-11-27
KR20140127262A (ko) 2014-11-03
BR112014017834A2 (pt) 2017-06-20
SG11201404032SA (en) 2014-08-28
ES2691635T3 (es) 2018-11-28
DOP2014000171A (es) 2014-08-15
LT2806893T (lt) 2018-12-10
AU2013213514B2 (en) 2017-07-13
PH12014501654A1 (en) 2014-10-13
UA116197C2 (uk) 2018-02-26
EA032208B1 (ru) 2019-04-30
CN104144702A (zh) 2014-11-12
CU24431B1 (es) 2019-07-04
PL2806893T3 (pl) 2019-01-31
AU2013213514A1 (en) 2014-08-07
AR089765A1 (es) 2014-09-17
PH12014501654B1 (en) 2014-10-13
JP6236401B2 (ja) 2017-11-22
RS57911B1 (sr) 2019-01-31
CA2861947A1 (en) 2013-08-01
CL2014001935A1 (es) 2015-04-10
UY34583A (es) 2013-09-02
WO2013110856A1 (en) 2013-08-01
IL233599A0 (en) 2014-08-31
EP2806893B1 (en) 2018-07-18
SI2806893T1 (sl) 2019-02-28
HK1203802A1 (en) 2015-11-06
PT2806893T (pt) 2018-11-09
MY172812A (en) 2019-12-12
HRP20181707T1 (hr) 2019-02-22
DK2806893T3 (en) 2018-11-05
JP2015504083A (ja) 2015-02-05

Similar Documents

Publication Publication Date Title
BR112014017834A8 (pt) Sistema de distribuição de fármacos
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
UY34832A (es) TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
CL2014001855A1 (es) Compuestos derivados de imidazopirrolidinona o sus sales, formas cristalinas; composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno o enfermedad mediada por la actividad de mdm2 y/o mdm4 tales como enfermedades proliferativas, especialmente cancer.
BR112013030599A2 (pt) núcleo absorvente para artigos absorventes descartáveis
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CR20150326A (es) Inhibidores de autotaxina
BR112018010671A2 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CL2013001073A1 (es) Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras.
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
BR112013014616A2 (pt) sistema terapêutico transdérmico para a administração de uma substância ativa
CL2014000490A1 (es) Compuestos derivados de pirazol y sus sales, con actividad inhibidora de sglt1; composicion farmaceutica que los comprende; y su uso para tratar o prevenir diabetes.
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat
WO2014188329A3 (en) Transdermal extended dosing of pramipexole for neurological disorders
EP3880175A4 (en) TEMPERATURE-REGULATING TRANSDERMAL DRUG DELIVERY SYSTEM
GT201300032A (es) Composicion farmaceutica de liberacion prolongada de trimetazidina
EA201490390A1 (ru) Вспомогательное средство для накладывания
CL2014001643A1 (es) Compuestos derivados de quinolina, como inhibidores de la enzima pde10a; composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno psiquiatrico o neurodegenerativo.
UY34755A (es) Agentes para el control de la glycaspis brimblecombei

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2706 DE 16-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.